European Commission Research & Innovation Initiatives and Programme Opportunities
Return to overview

European Partnership for Personalised Medicine (EP PerMed)

Snapshot overview

The European Partnership for Personalised Medicine (EP PerMed) supports synergies in research on personalised medicine across the European Union (EU) and its regional partners. The main objectives of the partnership are to (i) ensure a faster uptake of research and innovation (R&I) results into clinical practice and secure Europe’s position in state-of-the-art healthcare provision; (ii) facilitate approaches that take into account individual differences and better utilise the accumulating data to manage health, disease and its predisposition; (iii) contribute towards more sustainable healthcare systems and independence in data intensive healthcare.

Under the 2023-2024 work programme, one call for proposals was launched in 2023 and one in 2024. The latter is ongoing (deadline for pre-proposal submission closed).

Name

European Partnership for Personalised Medicine (EP PerMed)

Institution/ DG/ Agency responsible at EU-level

European Commission’s Directorate General for Research and Innovation (DG RTD)

Work programme

Horizon Europe Work Programme: Health (2023-2024)

Programme

EP PerMed is a partnership under Horizon Europe and is expected to last for 10 years (2023-2033).

Programme budget

The indicative total budget for the duration of the partnership is EUR 375 million, provided by the European Union and more than 50 international partners (mainly funding organisations from Europe and beyond).

Project budget

Depending on the specific call. For further detail, please see below:

  • European Partnership on Personalised Medicine:
      • Budget: EUR 100 million
      • Expected contributions: Around EUR 100 million
      • Indicative number of grants: 1
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets):
      • Budget: EUR 43,570,000
Type of funding

Grants, contribution may be required.

Target participants
  • European Partnership on Personalised Medicine:
      • Ministries in charge of R&I policy, as well as national and regional R&I and technology funding agencies and foundations
      • Ministries in charge of health and care policy, as well as national and regional healthcare authorities, organisations and providers
      • Other relevant Ministries and other key actors from civil society and end-users, research and innovation community, innovation owners, healthcare systems owners/organisers and healthcare agencies
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets):
      • Academia or research institutes
      • Clinical/public health sector
      • Private for-profit (industry) partners, e.g., small and medium-sized enterprises (SMEs) and private non-profit partners, e.g., foundations, associations or non-governmental organisations
Programme scope

There are three specific research and innovation objectives:

  • Integrating big data and ICT solutions for Health
  • Translating basic research into clinical applications
  • Providing socio-economic evidence for the uptake of personalised medicine by the healthcare systems
Participant criteria
  • European Partnership on Personalised Medicine:
      • European Union Member States
      • Countries associated to Horizon Europe
      • Low- and middle-income countries (LMICs)
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets):
      • Only transnational projects will be funded
      • Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call (see list above). Each of these partners must be eligible and request funding from the respective funding organisation. All three legal entities must be independent of each other
      • The project coordinator must be eligible to be funded by his/her regional/national participating funding organisation
Project duration
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets): 3 years
Average time from submission to project kick-off

The indicative timeline for evaluation and grant agreement, described in Annex F of the Horizon Europe Work Programme 2023-2024, is as follows:

  • Information on the outcome of the evaluation: Around 5 months from the deadline for submission
  • Indicative date for the signing of grant agreements: Around 8 months from the deadline for submission

For two-stage calls, the timing is different (for the evaluation result: around 3 months from the deadline for submission for the first stage and around 5 months from the deadline for submission for the second stage; for signature of the grant agreement: around 8 months from the second stage deadline for submission).

R&D stage

No specific stage but focus on personalised medicine

Intellectual property
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets):
      • Publication of the scientific outcomes of the project is mandatorily subject to open access. Research projects funded through EP PerMed are eligible to publish on Open Research Europe (ORE), an open access publishing platform of the EC.
Project database
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets): Overview here, Call for proposals here
Status
  • Identification or Validation of Targets for Personalised Medicine Approaches (PMTargets): Ongoing
      • Publication of the call: 02 January 2024
      • Deadline for pre-proposal submission: 05 March 2024
      • Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage: 20 May 2024
      • Deadline for full proposal submission: 20 June 2024
      • Rebuttal stage: August 2024
      • Communication of the funding decisions to the applicants: October 2024
      • Expected project start: End of 2024, beginning of 2025
Contact details & more information

EP PerMed – Overview
Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (PM)
Identification or Validation of Targets for Personalised Medicine Approaches – call

Return to overview

This tool was created by FTI Consulting for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

This tool was created by FTI Consulting
for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide: https://ec.europa.eu/docsroom/documents/42921
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:
    Monitoring

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:
    Monitoring

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain